Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial

American Heart Journal

Volumn 172, Issue , 2016, Pages 144-151

  Eisen, Alon ^a,b   Giugliano, Robert P ^a,b   Ruff, Christian T ^a,b   Nordio, Francesco ^a,b   Gogia, Harinder S ^a,c   Awasty, Vivek R ^a,d   Henderson, David A ^a,e   Mercuri, Michele F ^a,f   Rutman, Howard ^a,f   Antman, Elliott M ^a,b   Braunwald, Eugene ^a,b  

^a

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Anaheim Memorial Medical Center   (United States)

^d Marion General Hospital   (United States)

^e FLORIDA HOSPITAL   (United States)

^f DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; TREATMENT OUTCOME; BLOOD; BLOOD CLOTTING; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FIBRINOLYTIC THERAPY; METABOLISM; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROCEDURES; STROKE; UNITED STATES;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG APPROVAL; FACTOR XA; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PYRIDINES; STROKE; THIAZOLES; THROMBOLYTIC THERAPY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WARFARIN;

EID: 84959290935     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.11.004     Document Type: Article

References (18)

1. R.P. Giugliano, C.T. Ruff, E. Braunwald, and et al. Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 22 2013 2093 2104
2. C.T. Ruff, R.P. Giugliano, E. Braunwald, and et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial Lancet 385 9984 2015 2288 2295
3. K. Ogata, J. Mendell-Harary, M. Tachibana, and et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 2010 743 753
4. D.E. Salazar, J. Mendell, H. Kastrissios, and et al. Modeling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation Thromb Haemost 107 2012 925 936
5. G.Y. Lip, and G. Agnelli Edoxaban: a focused review of its clinical pharmacology Eur Heart J 35 28 2014 1844 1855
6. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420704.pdf
7. C.T. Ruff, R.P. Giugliano, E.M. Antman, and et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
8. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
9. D.W. Cockroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
10. B.N. Beasley, E.F. Unger, and R. Temple Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran N Engl J Med 364 19 2011 1788 1790
11. M.L. O'Donoghue, C.T. Ruff, R.P. Giugliano, and et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation Eur Heart J 36 23 2015 1470 1477
12. S. Barco, Y.W. Cheung, J.W. Eikelboom, and et al. New oral anticoagulants in elderly patients Best Pract Res Clin Haematol 26 2 2013 215 224
13. Y. Iguchi, K. Kimura, K. Kobayashi, and et al. Relation of atrial fibrillation to glomerular filtration rate Am J Cardiol 102 8 2008 1056 1059
14. M. Reinhard, E.J. Erlandsen, and E. Randers Biological variation of cystatin C and creatinine Scand J Clin Lab Invest 69 8 2009 831 836
15. B.F. Gage, A.D. Waterman, W. Shannon, and et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
16. G.Y. Lip, R. Nieuwlaat, R. Pisters, and et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation Chest 137 2 2010 263 272
17. G.Y. Lip, L. Frison, J.L. Halperin, and et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 57 2011 173 180
18. J.C. van Swieten, P.J. Koudstaal, M.C. Visser, and et al. Interobserver agreement for the assessment of handicap in stroke patients Stroke 19 1988 604 607